Breaking the Cycle

Activity Overview:

Systemic inflammation plays a central role in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), particularly among patients with chronic kidney disease (CKD), a represents a significant contributor to residual risk among patients living with these comorbid conditions. Novel and emerging treatment options seek to target this residual risk, however their integration into clinical care are challenged by suboptimal assessment of inflammatory risk in practice. For example, while high-sensitivity C-reactive protein (hsCRP) is a valuable biomarker for quantifying residual inflammatory risk, it is significant underutilized in real-world care. In this interactive symposium, expert faculty will seamlessly integrate real-world case vignettes with cutting-edge clinical data and panel discussions to highlight evolving considerations for the role of systemic inflammation in ASCVD and CKD; underscore the potential for emerging inflammation-targeted strategies, such as IL-6 inhibition) to address residual risk; and explore practical strategies to optimize the assessment of residual inflammatory risk in practice.

Target Audience:

This initiative is intended for general cardiology, heart failure specialists, and preventative cardiology, physicians, advanced practice providers, and other HCPs providing cardiorenal/cardiometabolic healthcare (e.g., nephrologists, endocrinologists).

Learning Objectives:

· Describe the role of systemic inflammation in the development and progression of ASCVD and CKD, including the bidirectional relationship between these conditions ​

· Apply evidence-based strategies to optimize the use of hsCRP in assessing residual inflammatory risk and guiding treatment decisions in ASCVD and CKD ​

· Assess emerging therapeutic strategies that target residual inflammatory risk to reduce CV events in patients with ASCVD and CKD, including their mechanisms of action, efficacy, and safety ​

· Evaluate the clinical implications of emerging inflammation-targeted therapies in ASCVD and CKD, including prospective considerations for clinical integration and their potential impact on patient outcomes

Commercial Support:

This activity is supported by an educational grant from Novo Nordisk.

Disclaimer:

This event is not part of the official Scientific Sessions 2025 as planned by the AHA Committee on Scientific Sessions Programming.

Accreditation Info:

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph*rm*cy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Criteria for Success

Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].

Host or Publisher Catalyst Medical Education, LLC